danieloday
Following are excerpts from CNBC interviews with Gilead Sciences, Inc. (NASDAQ:GILD) Chairman & CEO Daniel O’Day and Novavax, Inc. (NASDAQ:NVAX) President & CEO Stanley Erck on CNBC’s “Squawk on the Street” (M-F 9AM – 11AM ET) today, Monday, January 10. Following is a link to video on CNBC.com: Q4 2021 hedge fund letters, conferences and more Gilead CEO: Oral Version Of Covid Drug Remdesivir In Early TestingExcerpts from Gilead Sciences Chairman & CEO Daniel O’Day interview: O'Day On Impact Of RemdesivirDANIEL O’DAY: Remdesivir has really been, has had a major impact upon this pandemic over th...
ValueWalk
*CNBC Exclusive: CNBC Transcript: Gilead Sciences Chairman & CEO [Daniel O’Day](https://www.valuewalk.com/2020/08/astrazeneca-acquire-gilead-sciences/) speaks with CNBC’s “Squawk Box” today about raising full\-year guidance due to remdesivir sales\.* Q3 2020 hedge fund letters, conferences and more Gilead Sciences CEO On Raising Full-Year Guidance Due To Remdesivir SalesMEG TIRRELL: Dan, thanks for being with us this morning. Let's start with your news of the day. You raised your guidance for the full year now because of your Remdesivir sales looking at now $2.83 billion. Tell us about this gu...
ValueWalk
閲覧を続けるには、ノアドット株式会社が「プライバシーポリシー」に定める「アクセスデータ」を取得することを含む「nor.利用規約」に同意する必要があります。
「これは何?」という方はこちら